Incyte (INCY) Q2 2024 earnings summary

Executive summary

• Total revenues reached $1.044 billion in Q2 2024, up 9% year-over-year, driven by strong demand for Jakafi and Opzelura.

• Reported a GAAP net loss of $444.6 million for Q2 2024, compared to net income of $203.5 million in Q2 2023, primarily due to one-time R&D charges from the Escient acquisition.

• Completed the $2.0 billion share repurchase, reducing outstanding shares by 14.8%, and finalized the Escient Pharmaceuticals acquisition.

• Strategic pipeline transformation prioritized high-potential programs, discontinued lower-potential assets, and added two first-in-class medicines from Escient.

• Gained exclusive global rights to tafasitamab (Monjuvi/Minjuvi) through a $25 million asset acquisition.

Financial highlights

• Jakafi net product revenue was $706 million (+3% year-over-year), with paid demand up 9%; Opzelura net product revenue reached $122 million (+52% year-over-year), with U.S. prescriptions up 34% and refills up 50%.

• Total royalty revenues were $137 million, up 8% year-over-year; Minjuvi/Monjuvi revenues rose 136% to $31 million.

• GAAP net loss was $445 million, non-GAAP net loss was $396 million; diluted EPS was $(2.04) GAAP and $(1.82) non-GAAP.

• R&D expenses surged to $1.14 billion in Q2 2024, including $679–$691 million for Escient acquisition; excluding one-time items, R&D was $692 million, up 13%.

• Cash, cash equivalents, and marketable securities totaled $1.4 billion as of June 30, 2024, down from $3.7 billion at year-end 2023.

Outlook and guidance

• Raised 2024 Jakafi net revenue guidance to $2.71–$2.75 billion based on strong demand.

• Updated full-year 2024 R&D expense guidance to $1.755–$1.80 billion (GAAP), excluding $691 million in Escient acquisition costs.

• SG&A expenses projected at $1.21–$1.24 billion for 2024; maintained guidance for other hematology/oncology revenues and SG&A.

• Management expects Jakafi to remain the primary revenue driver for the next several years; Opzelura expected to continue growth with expanded European reimbursement.

• Cash flow, existing cash, and credit facility expected to be sufficient for foreseeable capital needs.